Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab in Anti-TNF Naïve Crohn's Disease
NCT02820493Phase 4Withdrawn
- Sponsor
- University of Genoa
- Start
- Sep 2016
- Primary completion
- Mar 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 4, open-label, single-arm trial of vedolizumab in Crohn's disease, sponsored by University of Genoa. Primary endpoint: Harvey Bradshaw Index at Week 14. Planned start Sep 2016; status: withdrawn.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02820493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02820493.